União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabine, tenofovir alafenamide, fumarate - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (ara sezzjoni 5.

União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirali għal użu sistemiku - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - aġenti antineoplastiċi - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - efavirenz, emtricitabine, tenofovir disoproxil fumarate - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - atripla hija taħlita ta 'doża fissa ta' efavirenz, emtricitabine u tenofovir disoproxil fumarate. huwa indikat għall-kura ta umana-1 (hiv-1) f'adulti b'soppressjoni viroloġika għal livelli hiv-1 rna ta ' < 50 kopja/ml fuq il-kombinazzjoni attwali tat-terapija antiretrovirali għal iktar minn tliet xhur. il-pazjenti ma jridux ikunu esperjenzaw falliment viroloġiku fuq xi qabel l-terapija mħallta antiretrovirali u għandhom ikunu magħrufa li ma kellhom razez tal-virus b'mutazzjonijiet li jikkonferixxu reżistenza sinifikanti għal xi wieħed mit-tliet komponenti kontenuti f'atripla qabel ma jinbeda l-ewwel reġim ta ' trattament antiretrovirali. id-dimostrazzjoni tal-benefiċċju ta 'atripla huwa bbażat primarjament fuq dejta minn 48 ġimgħa minn studju kliniku li fih il-pazjenti b'soppressjoni viroloġika stabbli fuq terapija antiretrovirali ta' kombinazzjoni bidlu għal atripla. l-ebda dejta ma hija disponibbli bħalissa minn studji kliniċi b'atripla fuq it-trattament naïve jew fil-pazjenti li ħadu trattament qawwi qabel. ebda dejta ma hija disponibbli biex tappoġġja l-kumbinazzjoni ta ' atripla u mediċini antiretrovirali oħra.

União Europeia - maltês - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, kobikistat, emtricitabine, tenofovir disoproxil fumarate - infezzjonijiet ta 'hiv - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - trattament tal-virus ta ' immunodefiċjenza umani 1 (hiv 1) infezzjoni fl-adulti età 18 snin jew aktar li huma naïve tat-trattament tal-antiretroviral jew li huma infettati bl-hiv 1 mingħajr mutazzjonijiet magħrufa assoċjati ma ' reżistenza għal kwalunkwe tat-tliet aġenti antiretroviral fl stribild.

União Europeia - maltês - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

União Europeia - maltês - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfoma, mantle-cell - aġenti antineoplastiċi - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).